Steve Edelman, MD

Expert endocrinologists provide final thoughts on addressing unmet needs and improving the management of T1D.

Schafer Boeder, MD, and Egils K. Bogdanovics, MD, share approaches to prevention, preservation, and replacement therapies for the treatment of T1D.

Experts in endocrinology share challenges of patient access to type 1 diabetes treatment as well as resources to combat these challenges.

Expert endocrinologists discuss implementing long-term monitoring of patients being treated with teplizumab for type 1 diabetes and review the PROTECT study for patients who are newly diagnosed with T1D.

Egils K. Bogdanovics, MD, and the expert panel review the TN10 study data on the efficacy of teplizumab in delaying the progression of T1D, which led to the drug’s approval from the FDA.

Justin M. Gregory, MD, MSCI, provides an overview of the mechanism of action of teplizumab and its use in delaying T1D.

Egils K. Bogdanovics, MD, and Schafer Boeder, MD, discuss interpreting antibody test results for type 1 diabetes and provide recommendations for retesting for those who have a negative test or have only 1 antibody present.

Linda A. DiMeglio, MD, reviews screening options for patients with a family history of T1D, highlighting TrialNet.

Expert endocrinologists discuss the clinical symptoms that prompt testing for T1D, as well the diagnostic testing tools that are available in clinical practice.

Justin M. Gregory, MD, MSC, reviews the risk factors of T1D, highlighting a family history of T1D and antibody screening.

Linda A. DiMeglio, MD, comments on the importance of early diagnosis of T1D, giving patients the advantage of preparing a treatment plan early.

Expert endocrinologists review the importance of staging and classifying T1D, highlighting dysglycemia.

Justin M. Gregory, MD, MSC, and Linda A. DiMeglio, MD, provide an overview of the pathophysiology of type 1 diabetes.

Schafer Boeder, MD, discusses the incidence of type 1 diabetes, highlighting risk factors such as age and family history.